Skip to main content
Modalis Therapeutics Corporation logo

Modalis Therapeutics Corporation — Investor Relations & Filings

Ticker · 4883 ISIN · JP3922600006 T Manufacturing
Open in API
Filings indexed 57 across all filing types
Latest filing 2025-03-27 Annual Report
Country JP Japan
Listing T 4883

About Modalis Therapeutics Corporation

https://modalistx.com/en/

Modalis Therapeutics Corporation is a biotechnology company developing precision genetic medicines for serious disorders. The company's core technology is CRISPR-GNDM®, a proprietary epigenome editing platform. This technology regulates the expression of specific genes—selectively activating or suppressing them—without altering the underlying DNA sequence or causing double-strand breaks. CRISPR-GNDM® utilizes a compact epigenome editor designed for efficient delivery to target cells using adeno-associated virus (AAV) vectors. The company advances its programs through a hybrid model of in-house development and collaborative partnerships, with a pipeline focused on therapeutic areas such as muscular disorders, cardiomyopathy, and central nervous system (CNS) disorders.

Recent filings

Filing Released Lang Actions
有価証券報告書－第9期(2024/01/01－2024/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains detailed financial statements, management discussion, and corporate information for the fiscal year ending December 31, 2024. The header explicitly identifies it as a 'Securities Report' (有価証券報告書) filed under the Financial Instruments and Exchange Act. FY 2024
2025-03-27 Japanese
臨時報告書
Audit Report / Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and is filed with the Kanto Local Finance Bureau. Section 1, '提出理由' (Reason for Submission), explicitly states that the company is submitting this report based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because the Board of Directors resolved to propose the 'Election of the Audit Corporation' to the upcoming General Shareholders' Meeting. Section 2, '報告内容' (Report Content), details the change in the audit corporation: the resignation of '有限責任 あずさ監査法人' (Ernst & Young ShinNihon LLC) and the proposed appointment of 'アルファ監査法人' (Alpha Audit Corporation). This document is a formal regulatory filing announcing a significant corporate governance change related to the statutory audit, which aligns perfectly with the definition of an Audit Report/Information filing (AR) or potentially a general Regulatory Filing (RNS). Given the specific nature of announcing the change of the statutory auditor, 'AR' (Audit Report / Information) is the most precise fit, as it covers regulatory stress tests and applied accounting principles/reports, and auditor changes are intrinsically linked to the audit function. It is not a full Annual Report (10-K) or an Earnings Release (ER). FY 2025
2025-02-21 Japanese
訂正有価証券届出書（組込方式）
Capital/Financing Update Classification · 98% confidence The document is titled "有価証券届出書" (Securities Registration Statement) and is filed with the "関東財務局長" (Kanto Local Finance Bureau Director). It details the offering of new securities, specifically "新株予約権付社債" (Bonds with Stock Acquisition Rights) and "新株予約権証券" (Stock Acquisition Rights Certificates), including specific amounts, issuance terms, redemption methods, and conversion price adjustments. This structure and content strongly indicate a formal regulatory filing related to capital raising or financing activities, which aligns best with the 'Capital/Financing Update' category (CAP) or potentially a general regulatory filing (RNS). Given the explicit focus on the terms of issuing convertible bonds and stock acquisition rights, 'CAP' is the most precise fit, as it covers company fundraising and capital structure changes. The document is comprehensive, not just an announcement of a report (ruling 2 does not apply).
2024-08-13 Japanese
半期報告書－第9期(2024/01/01－2024/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Modalis Therapeutics Corporation in Japan. It covers the interim accounting period from January 1, 2024, to June 30, 2024. It contains detailed financial statements, management analysis (MDA), and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-13 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO and CFO regarding the accuracy of the company's interim report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type like an interim report. H1 2024
2024-08-13 Japanese
有価証券届出書（組込方式）
Capital/Financing Update Classification · 98% confidence The document is titled "有価証券届出書" (Securities Registration Statement) and is submitted to the Kanto Local Finance Bureau Director ("関東財務局長"). It details the offering of new securities, specifically "新株予約権付社債" (Bonds with Stock Acquisition Rights) and "新株予約権証券" (Stock Acquisition Rights Certificates), along with the amounts being raised. This structure and terminology strongly indicate a formal filing related to capital raising or financing activities under Japanese financial regulations. Among the provided codes, "CAP" (Capital/Financing Update) is the most appropriate classification for a Securities Registration Statement detailing the issuance of convertible bonds and stock acquisition rights for fundraising purposes. The document is comprehensive, not just an announcement of a report (ruling 2 does not apply), and clearly focuses on capital structure changes/fundraising.
2024-08-07 Japanese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.